BioMarin Pharmaceutical Inc. (BMV:BMRN)

Market Cap	209.56B
Revenue (ttm)	57.77B
Net Income (ttm)	12.39B
Shares Out	n/a
EPS (ttm)	64.10
PE Ratio	16.91
Forward PE	12.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25
Average Volume	147
Open	1,107.00
Previous Close	n/a
Day's Range	1,107.00 - 1,107.00
52-Week Range	1,053.00 - 1,700.00
Beta	n/a
RSI	37.00
Earnings Date	Aug 1, 2025

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 3,040
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BMRN

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Financial numbers in USD